Across TCGA pan-cancer cohorts, TRAV2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAV2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TRAV2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV2 expression acts as an unfavorable survival marker.

UCEC and SKCM are the cancer types where TRAV2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →
SKCM	DFS	Median	II,III,IV	0.135	0.712	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRAV2 tumor-vs-normal RNA expression · all TRAV2 data types